MedPath

SFAKIANOS JOHN

🇬🇷Greece
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 2
1 (100.0%)

A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer

Phase 2
Recruiting
Conditions
Non-Muscle Invasive Bladder Urothelial Carcinoma
Non-muscle Invasive Bladder Cancer
Interventions
First Posted Date
2024-07-16
Last Posted Date
2025-05-04
Lead Sponsor
John Sfakianos
Target Recruit Count
60
Registration Number
NCT06503614
Locations
🇺🇸

Icahn School of Medicine at Mount Sinai, New York, New York, United States

News

No news found
© Copyright 2025. All Rights Reserved by MedPath